Acetylcholinesterase inhibition attenuates the development of hypertension and inflammation in spontaneously hypertensive rats

American Journal of Hypertension

Volumn 28, Issue 10, 2015, Pages 1201-1208

  Lataro, Renata M ^a   Silva, Carlos A A ^a   Tefé Silva, Cristiane ^a   Prado, Cibele M ^a   Salgado, Helio C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

autonomic dysfunction; blood pressure; donepezil; hypertension; pharmacological therapy; pyridostigmine; vagal stimulation

Indexed keywords

CHOLINESTERASE INHIBITOR; COLLAGEN; CYTOKINE; DONEPEZIL; GAMMA INTERFERON; INTERLEUKIN 6; METHYLATROPINE; PYRIDOSTIGMINE; TUMOR NECROSIS FACTOR ALPHA; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTERIAL PRESSURE; ARTICLE; ATTENUATION; BLOOD BRAIN BARRIER; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; HEART; HEART MUSCLE CELL; HEART RATE VARIABILITY; HYPERTENSION; INFLAMMATION; MALE; NONHUMAN; PLASMA; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE RATE; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TREATMENT DURATION; VAGUS TONE; ANIMAL; BLOOD; BLOOD PRESSURE; DRUG EFFECTS; HEART RATE; HEART VENTRICLE REMODELING; PRECLINICAL STUDY; WISTAR KYOTO RAT;

ANIMALS; BLOOD PRESSURE; CHOLINESTERASE INHIBITORS; CYTOKINES; DRUG EVALUATION, PRECLINICAL; HEART; HEART RATE; HYPERTENSION; INDANS; INFLAMMATION; MALE; PIPERIDINES; PYRIDOSTIGMINE BROMIDE; RATS, INBRED SHR; RATS, INBRED WKY; VENTRICULAR REMODELING;

EID: 84942269532     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpv017     Document Type: Article

References (39)

1. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res 2014; 114:1804-1814.
2. Handa T, Katare RG, Kakinuma Y, Arikawa M, Ando M, Sasaguri S, Yamasaki F, Sato T. Anti-Alzheimer's drug, donepezil, markedly improves long-Term survival after chronic heart failure in mice. J Card Fail 2009; 15:805-811.
3. Inanaga K, Ichiki T, Miyazaki R, Takeda K, Hashimoto T, Matsuura H, Sunagawa K. Acetylcholinesterase inhibitors attenuate atherogenesis in apolipoprotein E-knockout mice. Atherosclerosis 2010; 213:52-58.
4. Shi P, Diez-Freire C, Jun JY, Qi Y, Katovich MJ, Li Q, Sriramula S, Francis J, Sumners C, Raizada MK. Brain microglial cytokines in neurogenic hypertension. Hypertension 2010; 56:297-303.
5. Lataro RM, Silva CA, Fazan R Jr, Rossi MA, Prado CM, Godinho RO, Salgado HC. Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure. Am J Physiol Regul Integr Comp Physiol 2013; 305:R908-R916.
6. Andersson U, Tracey KJ. Reflex principles of immunological homeostasis. Annu Rev Immunol 2012; 30:313-335.
7. Olofsson PS, Rosas-Ballina M, Levine YA, Tracey KJ. Rethinking inflammation: neural circuits in the regulation of immunity. Immunol Rev 2012; 248:188-204.
8. Taylor P: Anticholinesterase agents. In Hardman JG, Limbird LE, Gilman AG (ed), Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 10th ed. New York, McGraw-Hill, 2001, pp. 175-192.
9. Okazaki Y, Zheng C, Li M, Sugimachi M. Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure. J Physiol Sci 2010; 60:67-74.
10. Sugimoto H. Donepezil hydrochloride: a treatment drug for Alzheimer's disease. Chem Rec 2001; 1:63-73.
11. Reale M, Iarlori C, Gambi F, Lucci I, Salvatore M, Gambi D. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients. Exp Gerontol 2005; 40:165-171.
12. Trott DW, Harrison DG. The immune system in hypertension. Adv Physiol Educ 2014; 38:20-24.
13. Dickhout JG, Lee RM. Blood pressure and heart rate development in young spontaneously hypertensive rats. Am J Physiol 1998; 274:H794-H800.
14. Kant GJ, Bauman RA, Feaster SR, Anderson SM, Saviolakis GA, Garcia GE. The combined effects of pyridostigmine and chronic stress on brain cortical and blood acetylcholinesterase, corticosterone, prolactin and alternation performance in rats. Pharmacol Biochem Behav 2001; 70:209-218.
15. Barnes CA, Meltzer J, Houston F, Orr G, McGann K, Wenk GL. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 2000; 99:17-23.
16. Garofalo MA, Kettelhut IC, Roselino JE, Migliorini RH. Effect of acute cold exposure on norepinephrine turnover rates in rat white adipose tissue. J Auton Nerv Syst 1996; 60:206-208.
17. Zubcevic J, Waki H, Raizada MK, Paton JF. Autonomic-immunevascular interaction: an emerging concept for neurogenic hypertension. Hypertension 2011; 57:1026-1033.
18. Harrison DG. The mosaic theory revisited: common molecular mechanisms coordinating diverse organ and cellular events in hypertension. J Am Soc Hypertens 2013; 7:68-74.
19. Awasthi H, Kaushal D, Siddiqui HH. Chronic inhibition of central Angiotensin-converting enzyme ameliorates colchicine-induced memory impairment in mice. Sci Pharm 2012; 80:647-662.
20. Pavlov VA, Parrish WR, Rosas-Ballina M, et al. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav Immun 2009; 23:41-45.
21. Peter C, Schmidt K, Hofer S, Stephan M, Martin E, Weigand MA, Walther A. Effects of physostigmine on microcirculatory alterations during experimental endotoxemia. Shock 2010; 33:405-411.
22. Akinci SB, Ulu N, Yondem OZ, Firat P, Guc MO, Kanbak M, Aypar U. Effect of neostigmine on organ injury in murine endotoxemia: missing facts about the cholinergic antiinflammatory pathway. World J Surg 2005; 29:1483-1489.
23. Kox M, Pompe JC, Peters E, Vaneker M, van der Laak JW, van der Hoeven JG, Scheffer GJ, Hoedemaekers CW, Pickkers P. α7 nicotinic acetylcholine receptor agonist GTS-21 attenuates ventilator-induced tumour necrosis factor-α production and lung injury. Br J Anaesth 2011; 107:559-566.
24. Sabino JP, da Silva CA, de Melo RF, Fazan R Jr, Salgado HC. The treatment with pyridostigmine improves the cardiocirculatory function in rats with chronic heart failure. Auton Neurosci 2013; 173:58-64.
25. Grassi G, Bombelli M, Brambilla G, Trevano FQ, Dell'oro R, Mancia G. Total cardiovascular risk, blood pressure variability and adrenergic overdrive in hypertension: evidence, mechanisms and clinical implications. Curr Hypertens Rep 2012; 14:333-338.
26. Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol 2013; 10:143-155.
27. Levy MN. Sympathetic-parasympathetic interactions in the heart. Circ Res 1971; 29:437-445.
28. Bombelli M, Facchetti R, Carugo S, Madotto F, Arenare F, Quarti-Trevano F, Capra A, Giannattasio C, Dell'Oro R, Grassi G, Sega R, Mancia G. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens 2009; 27:2458-2464.
29. Frohlich ED. Pathogenesis of hypertensive left ventricular hypertrophy and diastolic dysfunction. In Izzo Jr JL, Sica DA, Black HR (ed), Hypertension Primer: the essentials of high blood pressure, 4th ed. Dallas, American Heart Association, 2008, pp. 188-190.
30. Pepine CJ. The impact of nitric oxide in cardiovascular medicine: untapped potential utility. Am J Med 2009; 122:S10-S15.
31. Grassi G, Seravalle G, Dell'Oro R, Mancia G. Sympathetic mechanisms, organ damage, and antihypertensive treatment. Curr Hypertens Rep 2011; 13:303-308.
32. Manabe N, Foldes FF, Torocsik A, Nagashima H, Goldiner PL, Vizi ES. Presynaptic interaction between vagal and sympathetic innervation in the heart: modulation of acetylcholine and noradrenaline release. J Auton Nerv Syst 1991; 32:233-242.
33. Watanabe AM, Lindemann JP, Fleming JW. Mechanisms of muscarinic modulation of protein phosphorylation in intact ventricles. Fed Proc 1984; 43:2618-2623.
34. Rocha-Resende C, Roy A, Resende R, Ladeira MS, Lara A, de Morais Gomes ER, Prado VF, Gros R, Guatimosim C, Prado MA, Guatimosim S. Non-neuronal cholinergic machinery present in cardiomyocytes offsets hypertrophic signals. J Mol Cell Cardiol 2012; 53:206-216.
35. Howes LG. Cardiovascular effects of drugs used to treat Alzheimer's disease. Drug Saf 2014; 37:391-395.
36. Kubo T, Sato T, Noguchi T, Kitaoka H, Yamasaki F, Kamimura N, Shimodera S, Iiyama T, Kumagai N, Kakinuma Y, Diedrich A, Jordan J, Robertson D, Doi YL. Influences of donepezil on cardiovascular system-possible therapeutic benefits for heart failure-donepezil cardiac test registry (DOCTER) study. J Cardiovasc Pharmacol 2012; 60:310-314.
37. Isik AT, Yildiz GB, Bozoglu E, Yay A, Aydemir E. Cardiac safety of donepezil in elderly patients with Alzheimer disease. Intern Med 2012; 51:575-578.
38. Nordstrom P, Religa D, Wimo A, Winblad B, Eriksdotter M. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J 2013; 34:2585-2591.
39. Sato T, Urbano R, Yu C, Yamasaki F, Sato T, Jordan J, Robertson D, Diedrich A. The effect of donepezil on cardiovascular mortality. Clin Pharmacol Ther 2010; 88:335-338.